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Abstract 
Purpose: To investigate the protective effect of baicalein against chronic seizures in pentylenetetrazole 
induced epilepsy in a rat model.  
Methods: A rat model of chronic epilepsy was prepared by administration of pentylenetetrazole at a 
dose of 35 mg/kg to Sprague-Dawley rats. The animals were divided into 6 groups (5 rats/group): 
normal control, model (untreated epilepsy) and four treatment groups that received separately, 
intraperitoneal injection of 20, 30, 40 and 50 mg/kg baicalein, respectively, on alternate days for 30 
days. On each day following baicalein treatment, behavioural alterations in the rats were assessed.  
Results: Analyses of behavioural changes revealed significant (p < 0.05) decrease in 
pentylenetetrazole-induced convulsions by baicalein treatment at a dose of 50 mg/kg. 
Immunohistochemical studies revealed that treatment with baicalein caused significant (p < 0.05) dose-
dependent reductions in the levels of inducible nitric oxide synthase (iNOS). Baicalein treatment 
inhibited alterations in cell morphology, and also inhibited pentylenetetrazole-induced increase in the 
proportion of glial fibrillary acidic protein (GFAP)-positive cells in a dose-dependent manner (p < 0.05). 
Real-time polymerase chain reaction (RT-PCR) analysis showed that baicalein significantly inhibited the 
expression of mRNA of NR1 subunit N methyl D aspartic acid (NMDA) receptor, without any effect on 
the expression of the NR2b (N-methyl D-aspartate receptor subtype 2B ) subunit mRNA  (p < 0.05). 
Conclusion: These results indicate that baicalein inhibits pentylenetetrazole-induced chronic seizures 
in rats via reduction in astrocytes, inhibition of neuronal death and reduction of NR1 mRNA expression. 
Thus, baicalein has a potential for development into a new drug for the treatment of chronic epilepsy. 
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The flavone, 5, 6, 7-trihydroxyflavone, known as 
baicalein (Figure 1), is a natural isolate obtained 
from Scutellaria baicalensis Georgi. Baicalein 
has for long been an important component of 
traditional Chinese medicine [1]. It is used for 
treating ischemia and inflammatory diseases [1]. 
In vascular smooth muscle cells, baicalein 
attenuates endothelium intimal hyperplasia 
through inhibition of various pathways involved in 
inflammatory signalling, such as extracellular 
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signal-regulated kinase (ERK), serine threonine 
kinase (Akt) and nuclear factor-κB (NF-κB) [2]. In 
the mouse model of radiation-induced 
inflammation, baicalein treatment inhibited 
inflammation by targeting the Forkhead family of 
transcription factors and NF-κB [3]. Baicalein 
also exhibits anticancer properties, and has been 
shown to inhibit colorectal cancer [4]. In prostate 
carcinoma cells, studies have shown that 
baicalein suppressed the rate of cell proliferation, 
and inhibited metastatic and migration potential 
[5]. Thus baicalein possesses promising anti-
inflammatory properties. 
 
The death of neurons due to chronic seizures 
increases the susceptibility of the hippocampal 
tissues to further degradation, resulting in the 
development of chronic epilepsy [6]. Studies 
have revealed that administration of 
pentylenetetrazole leads to loss of neurons, 
resulting in chronic seizures [7]. The 
inflammatory factor, nitric oxide synthase is one 
of the prominent agents for induction of seizures 
[8, 9]. In the present study, the protective effect 
of baicalein against pentylenetetrazole-induced 









Animals and treatment protocol 
 
Thirty Sprague-Dawley rats (weighing 180 - 200 
g) were obtained from the Shanghai Laboratory 
Animal Centre (SLAC, Shanghai, China). The 
animals were assigned randomly to 6 groups (5 
rats/group): normal control, model and four 
treatment groups which were separately and 
intraperitoneally injected 20, 30, 40 and 50 mg/kg 
baicalein. The animal model of chronic epilepsy 
was prepared by intraperitoneal administration of 
35 mg/kg pentylenetetrazole for 28 consecutive 
days. Baicalein was injected on alternate days 
for 30 days. This study was performed in line 
with the guidelines contained in the Guide for the 
Care and Use of Laboratory Animals of the 
National Institute of Health [10]. All the 
experimental procedures were approved by the 
Institutional Animal Care and Use Committee 
(IACUC) of the First Affiliated Hospital of 
Zhengzhou University, Zhengzhou, China 
(approval no. 109/ZUC). 
 
Analysis of alterations in rat behaviour 
 
Changes in the behaviour of the experimental 
rats were analysed on the day following each 
treatment with baicalein, for the 30 days of the 
study. A known five-point scale was used for the 
assessment of the stage of chronic seizure [8]. In 
this scale, no response, twitching of ear and 
face, body convulsion, jerking, side turn and 
seizure were assigned stages 1, 2, 3, 4 and 5, 
respectively. 
 
Extraction of hippocampus 
 
On day 31, the animals were sacrificed, and 
whole brains were excised. The brain material 
was divided into two halves. The right half was 
subjected to paraffin embedment, followed by 
thin sectioning. Half of the brain material from 
each animal was subjected to RT-PCR analysis. 
 
RNA extraction and reverse transcription-
polymerase chain reaction (RT-PCR) 
 
The total RNA from the hippocampus tissue was 
extracted using TRIzol reagent (Invitrogen Co., 
Carlsbad, CA). The extracted RNA was digested 
for 20 min using RNase-free DNase (Boehringer 
Mannheim, Indianapolis, IN) at 37 ˚C. The RNA 
samples (2μg-samples) were used for the 
synthesis of cDNA by incubation for 1 h at 37 ˚C 
with Avian Myeloblastosis Virus (AMV) reverse 
transcriptase (Amersham Corp., Arlington 
Heights, IL). Sequence amplification to desired 
primers was performed using polymerase chain 
reaction (PCR). For the purpose of amplification, 
Mastercycler (Eppendorf, Hamburg, Germany) 
was used. The cycling consisted of denaturation 
for 4 min at 94 ˚C, followed by 30 cycles of 30 
sec at 94 ˚C, 30 sec at 58 ˚C, 40 sec at 72 ˚C 
and then 10 min at 72 ˚C. After amplification, the 
samples were put in 1.5 % agarose gels followed 




The paraffin-embedded hippocampal tissue 
sections were de-paraffinized in boiling xylene. 
The sections were then stained with 
haematoxylin and eosin H & E). The stained 
sections were examined under light microscope 
(BX51M; Olympus, Tokyo, Japan; at a 
magnification of x 10) for changes in tissue 
morphology. 
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The paraffin-embedded hippocampus tissue 
sections were subjected to de-paraffinization in 
boiling xylene, followed by re-hydration in ethyl 
alcohol gradient. The sections were then treated 
with hydrogen peroxidase for blocking the activity 
of endogenous peroxidase enzyme. The tissue 
sections were then analysed for the expression 
of the activity of iNOS using rabbit anti-mouse 
primary antibodies (Santa Cruz Biotechnology, 
Inc.). The sections were examined and imaged 
using a Leica microscope equipped with a digital 




Statistical analysis was performed using SPSS 
18.0 statistical software (SPSS, Inc., Chicago, IL, 
USA). Data are expressed as mean ± standard 
error of the mean (SEM). Comparisons among 
multiple groups were performed using a one-way 
analysis of variance (ANOVA), and a least 
significant difference post hoc test. Values of p < 




Effect of baicalein on chronic seizures 
induced by pentylenetetrazole in rats 
 
A known five point scale [11] was used for the 
analysis of the effect of baicalein on convulsions 
caused by pentylenetetrazole in the rats. The 
seizure grades in the group treated with 50 
mg/kg baicalein were significantly lower than 
those in the model control group (p < 0.02; 
Figure 2). Although reduction in seizure grades 
was observed with baicalein at a dose of 30 






Figure 2: Inhibitory effect of baicalein on pentylenetetrazole-induced convulsions in rats. *p < 0.05 and **p < 0.02 
(untreated vs. 30 and 50 mg/kg groups, respectively). A, B, C, D, E and F stand for normal, model, 20 mg/kg, 30 
mg/kg and 50 mg/kg treatment groups, respectively 
 
Effect of baicalein on iNOS in pentylenetetrazole-treated rats 
 
There was a significant increase in iNOS level in the pentylenetetrazole-treated group, when 
compared to the normal control group (p < 0.05). However, baicalein treatment for 30 days led to 
significant and dose-dependent reductions in iNOS (p < 0.05, p < 0.02), with maximum reduction at a 
baicalein dose of 50 mg/kg (Figure 3). 
 
 
Figure 3: Effect of baicalein treatment on the expression of iNOS in pentylenetetrazole-treated rats. The rats 
were treated with 20, 30, 40 and 50 mg/kg of baicalein on alternate days for 30 days. *p < 0.05 and **p < 0.02 
baicalein groups vs. model group 
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Figure 4: Effect of 30 mg/kg and 50 mg/kg doses of baicalein on hippocampal neuronal injury in 




Figure 5: Effect of baicalein treatment on the population of GFAP-positive cells in rat hippocampus. Baicalein 
significantly reduced pentylenetetrazole-induced increases in hippocampal population of GFAP-positive cells. 
(x100) 
 
Effect of baicalein on pentylenetetrazole-
induced cell injury in rats 
 
Microscopic examination of the rat hippocampal 
tissues revealed presence of wide intercellular 
spaces, irregular cellular morphology and 
apoptotic cells in the pentylenetetrazole (model) 
group. However, baicalein treatment inhibited the 
alterations in cell morphology in a dose-
dependent manner (Figure 4). The morphologies 
of the hippocampus tissues of the rats in the 
normal control group were similar to those in the 
50 mg/kg baicalein treatment group. 
 
Effect of baicalein on astrocytic hyperplasia 
 
Pentylenetetrazole significantly increased the 
proportion of GFAP-positive cells in the rat 
hippocampus, when compared to the control 
group. However, treatment of the rats with 
baicalein dose-dependently inhibited the 
pentylenetetrazole-induced increases in the 
proportion of GFAP-positive cells ((p < 0.05; 
Figure 5). The proportion of GFAP-positive cells 
in the normal control and in the 50 mg/kg 
baicalein treatment groups were similar.  
 
Effect of baicalein on NMDA receptor level 
 
Results from RT-PCR analysis revealed a 
significant increase in the expression of NR1 
mRNA in the pentylenetetrazole group, when 
compared to the normal control group (p < 0.05). 
However, treatment of the rats with baicalein 
significantly inhibited the expression of NR1 
mRNA (Figure 6). Analysis of the NR2b mRNA 
level showed no changes in the 
pentylenetetrazole group relative to the normal 




Figure 6: Effect of baicalein on expression of NR1 
mRNA in the pentylenetetrazole-treated rats. RT-PCR 
analysis showed a significant reduction in the 
expression of NR1 mRNA in baicalein-treated rats, 




In the present study, the protective effect of 
baicalein on chronic seizures induced in rats by 
administration of pentylenetetrazole was 
investigated. The results revealed that baicalein 
treatment inhibited increases in proportion of 
astrocytes, and also inhibited neuronal loss and 
expression of NR1 mRNA in the rat 
hippocampus. It has been reported that the 
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development of chronic seizures as a result of 
neurological disorders in the rat model can be 
inhibited by administration of chemotherapeutic 
agents [8,12].  
 
The results from the present study demonstrate 
that baicalein inhibited pentylenetetrazole-
induced convulsions in the rat model at 
comparatively low doses. This is important, 
because existing anti-convulsive agents exhibit 
their effects at much higher doses [12]. 
Furthermore, in the rat model of 
pentylenetetrazole-induced chronic epilepsy, 
baicalein treatment markedly reduced seizure 
grades. These findings suggest that baicalein is 
an efficient anti-convulsive agent, relative to 
already-established anti-convulsive compounds. 
Studies in animal models have shown that the 
development and progression of chronic seizures 
is associated with the expression of iNOS [8,9]. 
 
The expression of iNOS is higher in the tissues 
of animals with chronic epilepsy [9]. In the 
present study pentylenetetrazole administration 
to rats increased the expression of iNOS. This is 
consistent with earlier reports. However, 
treatment of the rats with baicalein inhibited 
pentylenetetrazole-induced up-regulation of 
iNOS expression. These results suggest that 
baicalein inhibited development of chronic 
seizures in the rats through suppression of iNOS 
expression.  
 
During chronic seizures, neuronal death 
enhances the susceptibility of the hippocampal 
tissues to further degradation, leading to the 
development of chronic epilepsy [9]. 
Pentylenetetrazole administration to rats triggers 
neuronal death and leads to development of 
chronic seizures [13]. Results from the present 
study showed presence of large intercellular 
spaces and deranged cellular morphology in the 
rat hippocampal tissues after pentylenetetrazole 
administration. However, baicalein treatment 
reversed these changes in cellular morphology 
induced by pentylenetetrazole.  
 
Astrocytes are responsible for increasing the 
expression of cytokines which in turn initiate 
inflammatory processes in neuronal cells [14]. 
The population of astrocytes in the hippocampus 
of pentylenetetrazole-treated rats has been 
reported to be elevated, indicating the onset of 
epilepsy [15]. In the present study, 
pentylenetetrazole increased the proportion of 
GFAP-positive cells in rat hippocampus. 
However, the pentylenetetrazole-induced 
increase in the proportion of GFAP-positive cells 




The results obtained in this study strongly 
suggest that baicalein treatment is effective in 
the prevention of chronic seizures caused by 
administration of pentylenetetrazole in rats. It 
exerts this effect through reduction in astrocytes, 
inhibition of neuronal death and reduction of NR1 
mRNA expression. Thus, baicalein has a 
potential for use in the treatment of chronic 
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